Press Releases
Nov 4, 2025
COVID-19,Corporate and finance
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
Oct 7, 2025
COVID-19,Corporate and finance
Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment
Sep 19, 2025
Statement
COVID-19,Partnerships,Science & technology
Sanofi and Novavax Statement on Nuvaxovid™ COVID-19 vaccine for ACIP
Sep 4, 2025
COVID-19,Corporate and finance
Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment
Sep 3, 2025
Statement
COVID-19,Science & technology
Novavax Statement on Publicly Available COVID-19 Vaccine Data
Aug 27, 2025
COVID-19,Corporate and finance
Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.
Jun 11, 2025
COVID-19,Seasonal influenza
Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial
Apr 28, 2025
Statement
COVID-19
Latest update on U.S. FDA BLA for Novavax's COVID-19 Vaccine
Apr 23, 2025
Statement
COVID-19
Latest update on U.S. FDA BLA for Novavax's COVID-19 Vaccine
Showper page